La cadena de opciones muestra datos clave de las opciones de acciones de FOXO Technologies a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para FOXO Technologies..

FOXO Technologies (AMEX:FOXO) Bolsa, Cadena de Opciones

FOXO Technologies

FOXO Technologies Inc is a technology platform company focused on commercializing longevity science through products and services that serve the life insurance industry. The company's epigenetic technology applies AI to DNA methylation to identify molecular biomarkers of human health and aging. The company has two reportable business segments, FOXO Labs and FOXO Life. The Company manages and classifies its business into two reportable business segments: Healthcare; and Labs and Life.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ALVO

BBGI

BCAX

ELTX

FOXO

ISPC

JBHT

LYTS

MDXG

NATR

NUKK

OFIX

TMCI

TXNM

VIAV

WILC

Explora los mayores ganadores y perdedores en las operaciones previas al mercado. Descubre qué impulsó estos movimientos destacados.

Las acciones de Versus Systems (VS) aumentan un 71%; 20 acciones que se mueven en el premercado de EE.UU.

FOXO Technologies Inc. Class A Common Stock

FOXO Technologies Inc

FOXO Technologies Inc Warrants (01/08/2027)

AECOM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACM#NYSE">ACM</a>) has outperformed the market over the past 5 years by 8.41% on an annualized basis producing an average annual return of 22.42%. Currently, AECOM has a market capitalization of $14.84 billion. 
Buying $100 In ACM: If an investor had bought $100 of ACM stock 5 years ago, it would be worth $285.84 today based on a price of $112.21 for ACM at the time of writing.
<h3>AECOM's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749741314_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning AECOM Stock In The Last 5 Years

BMO Capital analyst Stephen MacLeod maintains North West Co (TSX:<a class="ticker" href="https://www.benzinga.com/stock/NWC#TSX">NWC</a>) with a Outperform and lowers the price target from C$60 to C$59.

Price Target

Analyst Ratings

TSX:NWC

BMO Capital Maintains Outperform on North West Co, Lowers Price Target to C$59

Citigroup analyst Anthony Pettinari maintains Core &amp; Main (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNM#NYSE">CNM</a>) with a Neutral and raises the price target from $56 to $62.

Citigroup Maintains Neutral on Core & Main, Raises Price Target to $62

BMO Capital analyst Kelly Bania maintains United Natural Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNFI#NYSE">UNFI</a>) with a Market Perform and lowers the price target from $32 to $25.

UNFI

BMO Capital Maintains Market Perform on United Natural Foods, Lowers Price Target to $25

BlackRock Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>) on Thursday outlined a plan to raise $400 billion in alternative assets by 2030 and increase total revenue from $20 billion to over $35 billion in the same period.
According to BlackRock&#8217;s <a href="https://s24.q4cdn.com/856567660/files/doc_presentations/2025/BLK-Investor-Day-2025-WEB.pdf" target="_blank" rel="noreferrer noopener">Investor Day 2025 presentation</a>, the asset manager detailed a long-term strategy focused on expanding its private market exposure and scaling its technology platforms. 
Private markets currently contribute 15% of total revenue, but BlackRock aims to grow that share to more than 30% by the end of the decade.
Also Read: <a href="https://www.benzinga.com/news/topics/25/06/45851858/psiquantum-eyes-750m-raise-as-blackrock-doubles-down-on-light-based-supercomputers-amid-nvidias-quantum-reversal" target="_blank" rel="noreferrer noopener">PsiQuantum Eyes $750M Raise As BlackRock Doubles Down On Light-Based Supercomputers Amid Nvidia&#8217;s Quantum Reversal</a>
The company plans to double adjusted operating income from $8 billion to $15 billion and expand market capitalization from $140 billion to $280 billion. It reported returning $9 billion to investors through private market realizations following its Global Infrastructure Partners acquisition.
At the end of the first quarter, BlackRock&#8217;s total Assets Under Management was $11.6 trillion, compared to $10.5 trillion in the prior year quarter.
The strategy includes integrating Preqin&#8217;s data into the Aladdin platform to support benchmarking and analytics for private markets. BlackRock expects to begin onboarding <a href="https://www.benzinga.com/24/11/42227693/blackrock-set-to-acquire-private-credit-manager-hps-for-12b-report" target="_blank" rel="noreferrer noopener">HPS Investment Partners</a> in the third quarter, enhancing capabilities in private credit and insurance.
Aladdin generated $1.6 billion in revenue in 2024, with a $20 billion addressable market opportunity. The firm also manages $50 billion in crypto-related assets, including Circle&#8217;s USDC reserves and the IBIT bitcoin ETF.
Leadership roles were also highlighted, with CFO Martin Small and COO Rob Goldstein prominently featured in the strategy rollout, though CEO Larry Fink&#8216;s succession plan was not directly addressed.
Price Action: BLK shares are trading lower 0.26% to $990.70 at last check Thursday.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45891293/amex-still-king-of-premium-credit-cards-but-chase-capital-one-are-closing-in-" target="_blank" rel="noreferrer noopener">Amex Still King Of Premium Credit Cards — But Chase, Capital One Are Closing In Fast: Analyst</a></li>
</ul>
Photo via Shutterstock

Large Cap

BlackRock Targets $280 Billion Market Cap, $35 Billion Revenue By 2030

Guidance

Cardinal Health Expecting At Least $10B In Total Adjusted Free Cash Flow Over Next 3-Years; Raising Baseline Share Repurchase Plans To At Least $750M Per Year

BMO Capital analyst Keith Bachman maintains SailPoint (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIL#NASDAQ">SAIL</a>) with a Outperform and raises the price target from $26 to $27.

SAIL

BMO Capital Maintains Outperform on SailPoint, Raises Price Target to $27

BioNTech SE&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) on Thursday agreed to acquire CureVac N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVAC#NASDAQ">CVAC</a>) in an <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">all-stock transaction</a>.
According to the agreement, shareholders can exchange CureVac shares for around $5.46 in BioNTech ADSs. This equates, roughly, to an equity value of <a href="https://www.benzinga.com/pressreleases/25/06/g45900311/biontech-announces-strategic-transaction-to-acquire-curevac-in-public-exchange-offer" target="_blank" rel="noreferrer noopener">$1.25 billion</a>.
The consideration is subject to a collar mechanism. If the 10-day volume weighted average price of the BioNTech ADSs ending on the fifth business day before the offer&#8217;s closing exceeds $126.55, the exchange ratio would be 0.04318. If the VWAP is lower than $84.37, the exchange ratio would be 0.06476.
At closing, CureVac shareholders expect to own between 4% and 6% of BioNTech.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45853393/robert-kennedy-jr-axes-entire-cdc-vaccine-panel-to-restore-public-trust-pfizer-moderna-other-biotech-stocks-drop-in-after-hours-trading" rel="noreferrer noopener">Robert Kennedy Jr Axes Entire CDC Vaccine Panel To &#8216;Restore Public Trust&#8217; — Pfizer, Moderna, Other Biotech Stocks Drop In After-Hours Trading</a>
With the acquisition, BioNTech aims to strengthen the research, development, manufacturing, and commercialization of investigational mRNA-based cancer immunotherapy.
The strategic transaction will complement BioNTech&#8217;s capabilities and proprietary technologies in mRNA design, delivery formulations, and manufacturing.
For BioNTech, this transaction marks the next milestone in the execution of its oncology strategy which focuses on two pan-tumor programs, mRNA-based cancer immunotherapy candidates, and BNT327, a PD-L1xVEGF-A bispecific antibody candidate.
Following the transaction&#8217;s closing, CureVac&#8217;s operating subsidiary will become a wholly owned subsidiary of BioNTech. As part of this plan, BioNTech will integrate CureVac&#8217;s research and manufacturing site in Tübingen.
The transaction was unanimously approved by BioNTech&#8217;s and CureVac&#8217;s management and supervisory boards. The transaction is expected to close in 2025.
As of March 31, BioNTech had 15.9 billion euros in cash, cash equivalents, <a href="https://www.benzinga.com/25/05/45205736/biontech-appoints-novartis-executive-as-finance-chief-reaffirms-2025-guidance-focuses-on-oncology-expansion" target="_blank" rel="noreferrer noopener">and security investments</a>.
Earlier in June, BioNTech and&nbsp;Bristol Myers Squibb&nbsp;&amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) entered into a co-development and <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45723383/bristol-myers-inks-11-billion-licensing-pact-with-biontech-for-bispecific-cancer-drug" rel="noreferrer noopener">co-commercialization agreement</a>.
The pact focuses on BioNTech&#8217;s investigational bispecific antibody BNT327 across numerous solid tumor types.
Bristol Myers Squibb will pay BioNTech $1.5 billion upfront and $2 billion in non-contingent anniversary payments through 2028.
In addition, BioNTech will be eligible to receive up to $7.6 billion in additional development, regulatory and commercial milestones.
In March, CureVac said the European Patent Office (EPO) confirmed the validity of CureVac&#8217;s European patent EP 3 708 668 B1 subject to amendments to specify <a target="_blank" href="https://www.benzinga.com/25/03/44535393/european-patent-office-rules-vaccine-developer-curevacs-amended-patent-valid-stock-jumps" rel="noreferrer noopener">the scope of protection</a>.
The opposition division largely dismissed BioNTech&#8217;s original opposition filed in April 2023, challenging the patent&#8217;s validity and maintaining it in amended form.
Price Action: BNTX stock is up 1.22% at $106.75, and CVAC stock is up 33.2% at $5.42 during the premarket session at the last check on Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/45887132/novavaxs-experimental-covid-19-influenza-combo-shot-shows-immune-response-among-older-adults-in-phase-3-trial" target="_blank" rel="noreferrer noopener">Novavax&#8217;s Experimental COVID-19-Influenza Combo Shot Shows Immune Response Among Older Adults In Phase 3 Trial</a></li>
</ul>
Image: Shutterstock

Biotech

Health Care

General

BNTX

CVAC

NVAX

BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal

Cardinal Health Raises FY25 Non-GAAP Diluted EPS Guidance To $8.15 - $8.20

DA Davidson analyst Rudy Kessinger maintains CyberArk Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYBR#NASDAQ">CYBR</a>) with a Buy and raises the price target from $435 to $465.

CYBR

DA Davidson Maintains Buy on CyberArk Software, Raises Price Target to $465

Preliminary fiscal year 2026 guidance The company is providing preliminary guidance for fiscal year 2026:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Non-GAAP diluted EPS</td>
<td colspan="1" rowspan="1">
$9.10 to $9.30
(+13% growth at mid-points)
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted free cash flow</td>
<td colspan="1" rowspan="1">$2.75B to $3.25B</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Capital expenditures</td>
<td colspan="1" rowspan="1">~$600M</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Interest and other</td>
<td colspan="1" rowspan="1">~$275M</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Non-GAAP effective tax rate</td>
<td colspan="1" rowspan="1">22% to 24%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Pharmaceutical and Specialty Solutions:</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Revenue</td>
<td colspan="1" rowspan="1">11% to 13% growth</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Segment profit (Reported)</td>
<td colspan="1" rowspan="1">10% to 12% growth</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Segment profit (Normalized)4</td>
<td colspan="1" rowspan="1">5% to 7% growth</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Global Medical Products and Distribution:</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Revenue</td>
<td colspan="1" rowspan="1">3% to 5% growth</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Segment profit</td>
<td colspan="1" rowspan="1">&nbsp;$140M+</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Other5:</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Revenue (Reported)</td>
<td colspan="1" rowspan="1">26% to 28% growth</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Segment profit (Reported)</td>
<td colspan="1" rowspan="1">25% to 27% growth</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Revenue (Normalized)4</td>
<td colspan="1" rowspan="1">10% to 12% growth</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Segment profit (Normalized)4</td>
<td colspan="1" rowspan="1">~10% growth</td>
</tr>
</tbody>
</table>
</figure>
Long-term targets The company is providing updated long-term targets (fiscal years 2026 to 2028 CAGRs3):
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Non-GAAP diluted EPS</td>
<td colspan="1" rowspan="1">12% to 14% growth</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Pharmaceutical and Specialty Solutions:</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Revenue</td>
<td colspan="1" rowspan="1">8% to 10% growth</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Segment profit (Reported)</td>
<td colspan="1" rowspan="1">7% to 9% growth</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Segment profit (Normalized)4</td>
<td colspan="1" rowspan="1">5% to 7% growth</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Global Medical Products and Distribution:</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Revenue</td>
<td colspan="1" rowspan="1">2% to 4% growth</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Segment profit</td>
<td colspan="1" rowspan="1">$50M+ of profit growth per year after FY26</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Other5:</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Revenue (Reported)</td>
<td colspan="1" rowspan="1">16% to 18% growth</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Segment profit (Reported)</td>
<td colspan="1" rowspan="1">15% to 17% growth</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Revenue (Normalized)4</td>
<td colspan="1" rowspan="1">10% to 12% growth</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Segment profit (Normalized)4</td>
<td colspan="1" rowspan="1">~10% growth</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp; Adjusted Free Cash Flow (FY26 to FY28 total)</td>
<td colspan="1" rowspan="1">At least $10B</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp; Share Repurchases (FY26 to FY28 total)</td>
<td colspan="1" rowspan="1">At least $2.25B</td>
</tr>
</tbody>
</table>
</figure>

Cardinal Health Provides Preliminary FY26 Guidance With Non-GAAP EPS Of $9.10-$9.30, Adj. FCF Of $2.75B-$3.25B, Capital Expenditures ~$600M, Sees Segment Revenue Growth Across Key Divisions; Updates Long-Term Targets Through 2028 Including 12% - 14% EPS CAGR And Revenue Growth Across Key Divisions

WIIM

LOVE

Lovesac shares are trading lower despite reporting better-than-expected Q1 results. The company announced plans to exit its Best Buy partnership, reduce its workforce by 8%, and incur $1.7M–$2.1M in related costs.

DA Davidson analyst Gil Luria maintains Oracle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) with a Neutral and raises the price target from $140 to $170.

ORCL

DA Davidson Maintains Neutral on Oracle, Raises Price Target to $170

HIPO

Hippo shares are trading higher after announcing the $100M sale of its homebuilder distribution network to Baldwin Group's Westwood and projecting 2028 gross written premiums above $2B.

DDOG

Datadog shares are trading higher after Needham maintained a Buy rating on the stock and raised its price target from $130 to $140.

Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) today announced new Phase 1b data showing encouraging&nbsp;antileukemic activity and a promising safety profile for bleximenib (JNJ-75276617) in combination with venetoclax and azacitidine (VEN + AZA) for the treatment of acute myeloid leukemia (AML) harboring KMT2A gene rearrangements (KMT2Ar) or NPM1 gene mutations (NPM1m). The study evaluated patients with newly diagnosed, intensive chemo-ineligible AML and relapsed or refractory AML.1 The results were featured in an oral presentation at the&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4447496-1&amp;h=3957088323&amp;u=https%3A%2F%2Fehaweb.org%2Fconnect-network%2Feha2025-congress&amp;a=2025+European+Hematology+Association+(EHA)+Congress">2025 European Hematology Association (EHA) Congress</a>&nbsp;(<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4447496-1&amp;h=3103175932&amp;u=https%3A%2F%2Flibrary.ehaweb.org%2Feha%2F2025%2Feha2025-congress%2F4159214%2Fandrew.h.wei.rp2d.determination.of.bleximenib.in.combination.with.ven2Baza.html%3Ff%3Dlisting%253D0%252Abrowseby%253D8%252Asortby%253D1%252Asearch%253Dbleximenib&amp;a=S137">S137</a>).

Johnson & Johnson Announces Bleximenib, Investigational Selective Menin Inhibitor, Shows Potential As Combination Therapy For Treatment Of Relapsed Or Refractory AML And Newly Diagnosed, Intensive Chemo-Ineligible AML

The Lovesac Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOVE#NASDAQ">LOVE</a>) shares are trading lower on Thursday after <a href="https://www.benzinga.com/pressreleases/25/06/g45900518/the-lovesac-company-reports-first-quarter-fiscal-2026-financial-results" target="_blank" rel="noreferrer noopener">reporting first-quarter results</a>.
The furniture retailer reported a loss of 73 cents per share, beating <a href="https://www.benzinga.com/earnings">the Street view of 83 cents loss</a>.
Quarterly sales of $138.37 million (+4.3% year over year) outpaced the analyst consensus estimate of $137 million. This growth was primarily driven by an 18.2% increase in showroom sales, offsetting an 8.9% decline in internet sales.
Also Read:<a target="_blank" href="https://www.benzinga.com/real-estate/25/06/45879650/americans-have-over-34t-in-wealth-trapped-in-home-equity-and-wall-street-is-trying-to-get-its-hands-on-as-much-of-it-as-possible" rel="noreferrer noopener"> Americans Have Over $34T In Wealth Trapped In Home Equity — And Wall Street Is Trying To Get Its Hands On As Much Of It As Possible</a>
Gross profit increased 3.2% year over year to $74.4 million. Gross margin declined by 60 basis points to 53.7% of net sales in first quarter of fiscal year 2026, compared to 54.3% in the same period last year. 
The drop was mainly due to a 230-basis-point decrease in product margin from increased promotional discounting, partially offset by lower inbound and outbound logistics costs.
The cash and equivalents balance as of May&nbsp;4, was $26.9 million as compared to $72.4 million as of May&nbsp;5, 2024.
Total merchandise inventory was $124.9 million as of May&nbsp;4, 2025 as compared to $94.7 million as of May&nbsp;5, 2024 primarily related to a planned stock inventory increase of $25.9 million coupled with an increase in freight capitalization of $5.1 million.
The company opened 11 new showrooms and closed 1, resulting in a total of 267 showrooms as of May 4, 2025.
The company also announced it has discontinued <a href="https://www.sec.gov/Archives/edgar/data/1701758/000162828025030861/love-20250504.htm" target="_blank" rel="noreferrer noopener">its</a> partnership with Best Buy Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) and plans to wind down the Best Buy shop-in-shop locations by the third quarter of fiscal 2026, aligning with its strategic initiative to accelerate its physical and ecommerce presence.
The company stated that broad macroeconomic challenges, such as inflation, high interest rates, increased tariff and trade restrictions, and a weak housing market, are negatively impacting its business. These factors have led to a slowdown in consumer demand for its products, a trend that the company warns may continue.
Lovesac expects second-quarter GAAP EPS loss between 83 cents and 58 cents, higher than the 26 cents loss estimate. Revenue guidance stands at $157 million–$166 million, compared to the $161.67 million consensus.
The company projects adjusted EBITDA&nbsp;loss in the range of $2 million to $7 million. Net loss is expected to be in the range of $8 million to $12 million.
For fiscal year 2026, the company projects adjusted EBITDA in the range of $48 million to $60 million. Lovesac reaffirms GAAP EPS guidance of $0.80–$1.36 vs. $1.03 estimate.
It also maintains sales outlook of $700 million–$750 million, in line with the $710.71 million consensus. Net income is expected to be in the range of $13 million to $22 million.
Price Action: LOVE shares are trading lower by 12.3% to $17.98&nbsp;at last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/45899298/automotive-and-apparel-companies-absorbed-tariff-costs-amid-better-than-expected-may-cpi-print-b" target="_blank" rel="noreferrer noopener">Automotive And Apparel Companies&#8217; Absorbed Tariff Costs&#8217; Amid Better Than Expected May CPI Print: &#8216;But Don&#8217;t Expect That To Continue,&#8217; Says Expert</a></li>
</ul>
Photo via Shutterstock

Earnings

Equities

Furniture Retailer Lovesac Ends Best Buy Partnership, Issues Weak Forecast

A substantial insider sell was reported on June 11, by Charles E. Collins, Chief Executive Officer at Argan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGX#NYSE">AGX</a>), based on the recent SEC filing.
What Happened: A Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000100591/000141588925016657//Archives/edgar/data/100591/000141588925016657/0001415889-25-016657-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday outlined that Collins executed a sale of 1,265 shares of Argan with a total value of $305,231.
Argan shares are trading down 1.5% at $220.94 at the time of this writing on Thursday morning.
<h3>Unveiling the Story Behind Argan</h3>
Argan Inc is a United States-based construction firm that conducts operations through its wholly-owned subsidiaries, GPS, APC, TRC, and SMC. Through GPS and APC it provides a full range of engineering, procurement, construction, commissioning, maintenance, project development and technical consulting services to the power generation market, including the renewable energy sector, for a wide range of customers, including independent power project owners, public utilities, power plant heavy equipment suppliers and other commercial firms with power requirements in the U.S., Ireland and the U.K. It operates in three segments: Power Services, Industrial Services, and Telecom Services, out of which Power Services derives the majority of revenue.
<h3>Argan: Delving into Financials</h3>
Revenue Growth: Argan's revenue growth over a period of 3 months has been noteworthy. As of 30 April, 2025, the company achieved a revenue growth rate of approximately 22.82%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Industrials sector.
Profitability Metrics: Unlocking Value
<ul>
<li>
Gross Margin: The company issues a cost efficiency warning with a low gross margin of 19.03%, indicating potential difficulties in maintaining profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Argan's EPS is a standout, portraying a positive bottom-line trend that exceeds the industry average with a current EPS of 1.65.
</li>
</ul>
Debt Management: With a below-average debt-to-equity ratio of 0.01, Argan adopts a prudent financial strategy, indicating a balanced approach to debt management.
Financial Valuation Breakdown:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current P/E ratio of 31.28 is below industry norms, indicating potential undervaluation and presenting an investment opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 3.46, Argan's stock is perceived as being overvalued in the market, particularly in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): A high EV/EBITDA ratio of 22.44 positions the company as being more valued compared to industry benchmarks.
</li>
</ul>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Unmasking the Significance of Insider Transactions</h3>
Insider transactions contribute to decision-making but should be supplemented by a comprehensive investment analysis.
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Unlocking the Meaning of Transaction Codes</h3>
For <a href="https://www.benzinga.com/money/investing-tools">investors</a>, a primary focus lies on transactions occurring in the open market, as indicated in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000100591">Check Out The Full List Of Argan's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Insider Decision: Charles E. Collins Offloads $305K Worth Of Argan Stock

Making a noteworthy insider sell on June 11, DAVID DUVALL, Chief Executive Officer at Core Molding Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CMT#AMEX">CMT</a>), is reported in the latest SEC filing.
What Happened: DUVALL's decision to sell 6,260 shares of Core Molding Technologies was revealed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001026655/000102665525000059//Archives/edgar/data/1026655/000102665525000059/0001026655-25-000059-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday. The total value of the sale is $101,677.
The latest update on Thursday morning shows Core Molding Technologies shares down by 0.3%, trading at $16.5.
<h3>Delving into Core Molding Technologies's Background</h3>
Core Molding Technologies Inc operates in the engineered materials market as one operating segment as a molder of thermoplastic and thermoset structural products. It produces and sells molded products for varied markets, including medium and heavy-duty trucks, automobiles, power sports, construction and agriculture, building products, and other industrial markets. The processes include compression molding of sheet molding compound (SMC), resin transfer molding (RTM), liquid molding of dicyclopentadiene (DCPD), spray-up and hand-lay-up, direct long-fiber thermoplastics (D-LFT) and structural foam, and structural web injection molding (SIM). It operates operates in Columbus, Ohio; Gaffney, South Carolina; Winona, Minnesota; Matamoros and Escobedo, Mexico; and Cobourg, Ontario, Canada.
<h3>Core Molding Technologies's Financial Performance</h3>
Decline in Revenue: Over the 3 months period, Core Molding Technologies faced challenges, resulting in a decline of approximately -21.37% in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. When compared to others in the Materials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Evaluating Earnings Performance:
<ul>
<li>
Gross Margin: The company sets a benchmark with a high gross margin of 19.18%, reflecting superior cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Core Molding Technologies's EPS is significantly higher than the industry average. The company demonstrates a robust bottom-line performance with a current EPS of 0.25.
</li>
</ul>
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.14.
Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a lower-than-average P/E ratio of 12.44, the stock indicates an attractive valuation, potentially presenting a buying opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: With a lower-than-average P/S ratio of 0.51, the stock presents an attractive valuation, potentially signaling a buying opportunity for investors interested in sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With an EV/EBITDA ratio lower than industry benchmarks at 4.11, Core Molding Technologies presents an attractive value opportunity.
</li>
</ul>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Delving Into the Significance of Insider Transactions</h3>
While insider transactions provide valuable information, they should be part of a broader analysis in making investment decisions.
In the realm of legality, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities under Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are required to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Notably, when a company insider makes a new purchase, it is considered an indicator of their positive expectations for the stock.
Conversely, insider sells may not necessarily signal a bearish stance on the stock and can be motivated by various factors.
<h3>Understanding Crucial Transaction Codes</h3>
Surveying the realm of stock transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often give prominence to those unfolding in the open market, systematically detailed in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001026655">Check Out The Full List Of Core Molding Technologies's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Core Molding Technologies Chief Executive Officer Sold $101K In Company Stock

Revealing a significant insider sell on June 11, Aoife McGrath, SVP at Coeur Mining (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CDE#NYSE">CDE</a>), as per the latest SEC filing.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0000215466/000021546625000117//Archives/edgar/data/215466/000021546625000117/0000215466-25-000117-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday showed that McGrath sold 8,000 shares of Coeur Mining. The total transaction amounted to $74,720. 
Tracking the Thursday's morning session, Coeur Mining shares are trading at $9.37, showing a up of 2.4%.
<h3>About Coeur Mining</h3>
Coeur Mining Inc is a metals producer focused on mining precious minerals in the Americas. It is involved in the discovery and mining of gold and silver and generates the vast majority of revenue from the sale of these precious metals. The operating mines of the company are palmarejo, Rochester, Wharf, and Kensington. Its projects are located in the United States, Canada, and Mexico.
<h3>Breaking Down Coeur Mining's Financial Performance</h3>
Revenue Growth: Over the 3 months period, Coeur Mining showcased positive performance, achieving a revenue growth rate of 69.0% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Materials sector, the company excelled with a growth rate higher than the average among peers.
Profitability Metrics: Unlocking Value
<ul>
<li>
Gross Margin: The company shows a low gross margin of 31.3%, suggesting potential challenges in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Coeur Mining's EPS is below the industry average. The company faced challenges with a current EPS of 0.06. This suggests a potential decline in earnings.
</li>
</ul>
Debt Management: With a below-average debt-to-equity ratio of 0.19, Coeur Mining adopts a prudent financial strategy, indicating a balanced approach to debt management.
Insights into Valuation Metrics:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current Price to Earnings ratio of 31.55 is higher than the industry average, indicating the stock is priced at a premium level according to the market sentiment.
</li>
<li>
Price to Sales (P/S) Ratio: With a relatively high Price to Sales ratio of 3.29 as compared to the industry average, the stock might be considered overvalued based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): A high EV/EBITDA ratio of 16.61 reflects market recognition of Coeur Mining's value, positioning it as more highly valued compared to industry peers.
</li>
</ul>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Importance of Insider Transactions</h3>
It's important to note that insider transactions alone should not dictate investment decisions, but they can provide valuable insights.
Within the legal framework, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as per Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
The initiation of a new purchase by a company insider serves as a strong indication that they expect the stock to rise.
However, insider sells may not always signal a bearish view and can be influenced by various factors.
<h3>Understanding Crucial Transaction Codes</h3>
Examining transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often concentrate on those unfolding in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000215466">Check Out The Full List Of Coeur Mining's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Selling: Aoife McGrath Unloads $74K Of Coeur Mining Stock

Press Releases

FOXO TECHNOLOGIES, INC., PROVIDES UPDATE ON RECENT ACOMPLISHMENTS AND BUSINESS STRATEGY

FOXO TECHNOLOGIES, INC. ANNOUNCES EXECUTION OF A NON-BINDING ACQUISITION AGREEMENT FOR TWO ASSISTED-LIVING FACILITIES IN FLORIDA FOR A TOTAL CONSIDERATION OF $60 MILLION

Comments

FOXO Technologies

FOXO Technologies (FOXO) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL